ACVR2A siRNA Set I(A35-911)

ACVR2A siRNA Set I(A35-911)

  • $595.00


Description :ACVR2A is a pool of three individual synthetic siRNA duplexes designed to knock-down human ACVR2A mRNA expression. Each siRNA is 19-25 bases in length.

Specificity :ACVR2A siRNAs are designed to specifically knock-down human ACVR2A expression.

Formulation :The siRNAs are supplied as a lyophilized powder and shipped at room temperature.

Reconstitution Protocol :Briefly centrifuge the tubes (maximum RCF 4,000g) to collect lyophilized siRNA at the bottom of the tube. Resuspend the siRNA in 50 ul of DEPC-treated water (supplied by researcher), which results in a 1x stock solution (10 uM). Gently pipet the solution 3-5 times to mix and avoid the introduction of bubbles. Optional: aliquot 1x stock solutions for storage.

Storage and Stability :The lyophilized powder is stable for at least 4 weeks at room temperature. It is recommended that the lyophilized and resuspended siRNAs are stored at or below -20oC. After resuspension, siRNA stock solutions ≥2 uM can undergo up to 50 freeze-thaw cycles without significant degradation. For long-term storage, it is recommended that the siRNA is stored at -70oC. For most favorable performance, avoid repeated Handling and multiple freeze/thaw cycles.

Format :Lyophilized powder

Gene Aliases :ACTRII; ACVR2

Scientific Background :ACVR2A encodes activin A type II receptor that are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins is an autocrine/paracrine regulator in the human placenta (1). ACVR2A is highly expressed in human brain and ovary (2). Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity.

References :
1. Donaldson, C. J. Molecular cloning and binding properties of the human type II activin receptor. Biochem. Biophys. Res. Commun. 184: 310-316, 1992.

2. Peng, C. Expression of the type II activin receptor gene in the human placenta. Endocrinology 133: 3046-3049,1993

Product Sheets (By Lot #) :


Research Areas :Cancer, Ser/Thr Kinases, Cancer, Cytoplasmic Tyrosine Kinases